戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  to treatment of macrophages with trypsin or heparinase.
2 PG and in HSPG-expressing cells treated with heparinase.
3  sensitive to both chondroitin ABC lyase and heparinase.
4 main, and by incubating the blastocysts with heparinase.
5 excess heparan sulfate and by treatment with heparinase.
6 sion was reversed by tetrahydrolipstatin and heparinase.
7  which was reversed by antifibrinolytics and heparinase.
8 y soluble heparin and by treating cells with heparinase.
9 rin or by the pretreatment of the cells with heparinase.
10 bolished when CHO-K1 cells were treated with heparinases.
11 ycosaminoglycans (GAGs) on the action of the heparinases.
12  broadest known substrate specificity of the heparinases.
13 age of entry was observed in CF treated with heparinases.
14 , however, contained three, compared to two, heparinase 1-resistant sequences separated by larger con
15                      Cellular treatment with heparinase and chondroitinase ABC inhibited expression b
16                   Pretreatment of cells with heparinase and heparitinase abolished more than 80% of t
17 ell surface heparan sulfate proteoglycans by heparinase and heparitinase but not by treatment with co
18 with the glycosaminoglycan-degrading enzymes heparinase and heparitinase suggesting the specific invo
19 was examined with or without the addition of heparinase and heparitinase to cell incubation mixtures.
20                                              Heparinase and heparitinase treatment of cells reduced b
21 rin formation) greater than 1 minute between heparinase and standard thrombelastogram (TEG) is associ
22      Among others, these enzymes include the heparinases and an unusual glycuronidase that hydrolyzes
23 on of heparin-like glycosaminoglycans by the heparinases and mutant heparinases could pave the way to
24 By disrupting (with sulfation inhibitors and heparinase) and partially reconstituting (with heparin)
25 ls and primary neurons by heparin, chlorate, heparinase, and genetic knockdown of a key HSPG syntheti
26                                              Heparinases are bacterial enzymes that are powerful tool
27 -like glycosaminoglycan degrading enzymes or heparinases are powerful tools that have enabled the elu
28 of porcine intestinal heparin with bacterial heparinase), as well as a heparin-derived pharmaceutical
29 fate from the cell surface by treatment with heparinase blocked HCV attachment.
30       Importantly, treatment with heparin or heparinase blocked LRP1-mediated cellular uptake of Abet
31 anced uptake was reduced by more than 80% by heparinase but was unaffected by the 39-kDa protein.
32 lost when intact cells were predigested with heparinases but not chondroitinases.
33 saccharides obtained through the controlled, heparinase-catalyzed depolymerization of heparin.
34 cess heparin or pretreatment of acini with a heparinase cocktail each inhibited Ad5 transduction by a
35 minating heparan sulfate proteoglycans using heparinase completely abrogated the mechanical induction
36 g distinctions in substrate specificities of heparinases could be used to isolate oligosaccharides wi
37 osaminoglycans by the heparinases and mutant heparinases could pave the way to the development of muc
38  independent means of disrupting syndecan-4: heparinase degradation of HS glycosaminoglycans or suppr
39        These proteoglycans were sensitive to heparinase, demonstrating that K562 cells synthesize bFG
40                                    The three heparinases derived from Flavobacterium heparinum are po
41  utility of this enzyme in the sequencing of heparinase-derived HSGAG oligosaccharides.
42  increased binding of both proteins, whereas heparinase digestion and competition with heparin/HS inh
43 pressing activity of EHS-BM was sensitive to heparinase digestion but not to chondroitinase ABC or hy
44  assay to assess the purity of heparin using heparinase digestion followed by size-exclusion HPLC ana
45                                              Heparinase digestion of the endothelial cell's glycocaly
46                      HIP was not released by heparinase digestion suggesting that the association is
47 ular epithelial cells and can be released by heparinase digestion.
48 tease (EC 3.4.21.16); (iv) lyase activity of heparinase (EC 4.1.1.7); and (v) ligase activity of pyru
49 end of oligosaccharides resulting from prior heparinase eliminative cleavage.
50      We recently described the P. aeruginosa heparinase-encoding gene, hepP, whose expression was sig
51 zation, while pretreatment of HIS cells with heparinase enzyme or with anti-3-OS HS (G2) peptide sign
52 chain, which it protects from degradation by heparinase enzymes.
53          Finally, pretreatment of cells with heparinase failed to abolish apoE inhibition of smooth m
54   Heparinase III is the unique member of the heparinase family of heparin-degrading lyases that recog
55                                          The heparinases from Flavobacterium heparinum are lyases tha
56                                          The heparinases from Flavobacterium heparinum are powerful t
57 ools used for the production of LMWH are the heparinases from Flavobacterium heparinum, specifically
58 , prostaglandin-endoperoxide synthase-2, and heparinase genes.
59 polymerization using the bacterially derived heparinases, given the structural understanding of their
60                                              Heparinase had no effect on adhesion to the peptide.
61 noglycans and treatment of target cells with heparinase had no significant inhibition on cytoadherenc
62                                 In addition, heparinases have significant therapeutic applications.
63                                              Heparinase/heparinitase treatment of the basolateral cel
64                            Cleavage of HS by heparinase, heparitinase, or heparanase severely reduced
65                     Treatment of matrix with heparinase/heparitinase (1 U/ml each) increased LDL bind
66  cysteine-135 as an important amino acid for heparinase I (EC 4.2.2.7) activity.
67 entified the primary heparin binding site of heparinase I (EC 4.2.2.7).
68 t, but did not change the product profile of heparinase I action on heparin; conversely, mutations in
69 w as 10 microM DEPC results in a 85% loss of heparinase I activity in 15 min.
70                                              Heparinase I activity is restored following hydroxylamin
71 raphy suggested that mutations in CB-1 alter heparinase I activity primarily through decreasing the e
72 nt, but they had a more pronounced effect on heparinase I activity, suggesting a different role for C
73 f the HB-1 region has a pronounced effect on heparinase I activity.
74  results in only a 2- to 3-fold reduction in heparinase I activity.
75 ng that these residues are not essential for heparinase I activity.
76 ride, we showed that the interaction between heparinase I and calcium was essential for proper functi
77 ave shown that calcium binds specifically to heparinase I and have identified two major calcium-bindi
78                              Given that both heparinase I and heparinase II contain catalytically cri
79 parinase III, and TRSB was sensitive to both heparinase I and heparinase III.
80 xperiments to answer the question of whether heparinase I binds to calcium and, if so, which regions
81 , strongly suggests that the inactivation of heparinase I by DEPC is specific for histidine residues.
82  60 nm) and that calcium is able to activate heparinase I catalytically.
83 to further understand the mechanism by which heparinase I cleaves its polymer substrate, we sought to
84  also identified a heparin binding domain in heparinase I containing two positively charged clusters
85 to investigate the sequence of events during heparinase I depolymerization of HLGAGs.
86 stions with individual enzymes revealed that heparinase I did not cleave at GlcNH(3)(+) residues; how
87 harides of known structure were subjected to heparinase I digestion and analyzed.
88 ) that are important for calcium binding and heparinase I enzymatic activity.
89 rinization of the circuit via an immobilized heparinase I filter.
90                                              Heparinase I from Flavobacterium heparinum has important
91                            In a second step, heparinase I has a strong preference for cleaving the sa
92                                The wild-type heparinase I has four histidine residues; site-directed
93 y, amino acids located in the active site of heparinase I have been identified and mapped.
94 erve concentration-dependent inactivation of heparinase I in the presence of reversible histidine-mod
95 bonate (DEPC); 0.3 mM DEPC results in 95% of heparinase I inactivation in less than 3 min, and as low
96              We show that heparin binding to heparinase I is independent of calcium (Kd of 60 nm) and
97                          In an initial step, heparinase I preferentially cleaves exolytically at the
98 hydryl selective labeling of cysteine 135 of heparinase I protects the lysines of the heparin binding
99    Pretreatment of monocytes with heparin or heparinase I resulted in partial inhibition of cell adhe
100 us to propose a model for calcium binding to heparinase I that includes both CB-1 and CB-2 providing
101 nd competition assays, to map the regions of heparinase I that interact specifically with heparin.
102 (Glu207-Ala219) and CB-2 (Thr373-Arg384), in heparinase I that not only are specifically modified by
103  heparin binding site, may bridge heparin to heparinase I through calcium in a ternary complex during
104 escent calcium analog terbium, we found that heparinase I tightly bound divalent and trivalent cation
105 e E2DeltaHVR1-G or E2-G pseudotypes, whereas heparinase I treatment (8 U/ml) of cells reduced 40% E2-
106 preparations of various molecular weights or heparinase I treatment of cells prevented HPV31b infecti
107 d an outer compartment where the immobilized heparinase I was fluidized separately from the blood cel
108                                              Heparinase I was immobilized onto agarose beads via cyan
109          Chemical and proteolytic digests of heparinase I were used in direct binding and competition
110                   However, H203A inactivates heparinase I while a H203D mutant has residual activity,
111 ations in CB-2 not only altered the kcat for heparinase I, but also resulted in incomplete degradatio
112 larly, pretreatment of eukaryotic cells with heparinase I, but not pretreatment of eukaryotic cells w
113 f a glycosidic linkage imparts resistance to heparinase I, II, and III cleavage.
114 ective digestion with pronase, NaOH/NaBH(4), heparinase I, or low pH nitrous acid showed that each HS
115 bition of granule activity by digestion with heparinase I, the failure of proteolysis of the proteogl
116 ing studies of Woodward's reagent K-modified heparinase I, we identified two putative calcium-binding
117 d GAGs examined were effective inhibitors of heparinase I, with IC(50) values ranging from approximat
118 ide evidence that one of the active sites is heparinase I-like, cleaving at hexosamine-sulfated iduro
119 ition of deoxycholic acid, or treatment with heparinase I.
120 n-like glycosaminoglycan depolymerization by heparinase I.
121 ent role for CB-2 in the enzymatic action of heparinase I.
122 cofactor without altering heparin binding to heparinase I.
123 ssary cofactor, in the enzymatic activity of heparinase I.
124 ve mechanism of depolymerization of HLGAG by heparinase I.
125 ne 203 together form the catalytic domain in heparinase I.
126 microenvironment for the catalytic domain of heparinase I.
127 zation of heparin-like glycosaminoglycans by heparinase I.
128 e data for degradation of polymeric HLGAG by heparinase I.
129 sidues together form the catalytic domain of heparinase I.
130 dine(s) lie(s) in or near the active site of heparinase I.
131 aran sulfate or cells that were treated with heparinase I.
132  was abrogated by pretreatment of cells with heparinase I.
133 ned in the heparin binding site) inactivated heparinase I; however, a H203D mutant retained marginal
134 hexasaccharide model compounds, we show that heparinases I and II, but not heparinase III, cleave the
135                   As previously observed for heparinases I and II, substrate protection experiments s
136  from Flavobacterium heparinum, specifically heparinases I and II.
137 to venular endothelial cells; treatment with heparinases I and III significantly reduced this binding
138      Treatment with keratanase (3 joints) or heparinases I, II and III (3 joints) caused no significa
139 letion by chondroitinase ABC, keratanase and heparinases I, II and III in vivo.
140 K5 polysaccharide by digestion with combined heparinases I, II, and III.
141 these results are due to residual HSPG since heparinase (I and III) digestion of chlorate-treated cel
142                                              Heparinase II (no EC number) is one of three lyases isol
143                                              Heparinase II activity is restored following hydroxylami
144 indicating that cysteine 348 is required for heparinase II activity toward heparin but is not essenti
145 importance of histidines 238, 451 and 579 in heparinase II activity.
146  out to investigate the role of cysteines in heparinase II activity.
147 nes 238, 451, and 579 as being important for heparinase II activity.
148 , strongly suggests that the inactivation of heparinase II by DEPC is specific for histidine residues
149                            We show here that heparinase II cleaves heparin-like glycosaminoglycans en
150             Given that both heparinase I and heparinase II contain catalytically critical histidines,
151 agenesis experiments on the 13 histidines of heparinase II corroborated the chemical modification and
152 n with heparan sulfate was unable to protect heparinase II from DEPC inactivation for either of the s
153                                              Heparinase II generated DeltaHexA-GlcNH(3)(+)(6S),DeltaH
154                    In addition, we show that heparinase II has two distinct active sites and provide
155 to investigate the role of the histidines of heparinase II in catalysis.
156 erve concentration-dependent inactivation of heparinase II in the presence of the reversible histidin
157 was found that one of the three cysteines in heparinase II is surface-accessible and possesses unusua
158                                              Heparinase II is unique among the heparinases in that it
159                                              Heparinase II is unique among the three enzymes because
160                                     However, heparinase II preincubation with heparan sulfate was una
161   Substrate protection experiments show that heparinase II preincubation with heparin followed by the
162                          Thus, the action of heparinase II requires O-sulfation, whereas heparinase I
163 cell lines with heparin, sodium chlorate, or heparinase II, demonstrating that heparin sulfate proteo
164 eparin-like glycosaminoglycan degradation by heparinase II, we set out to investigate the role of the
165 zation of heparin-like glycosaminoglycans by heparinase II, which possesses the broadest known substr
166 ysteine 189 are functionally unimportant for heparinase II.
167 not cleave at GlcNH(3)(+) residues; however, heparinases II and III showed selective and distinct act
168 ted completely by pretreatment with 15 mU/mL heparinase III (E.C.4.2.2.8) for 2 hours.
169 , removal of cell-surface heparan sulfate by heparinase III abolished the chemorepulsive response to
170 or cell treatment with chondroitinase ABC or heparinase III abolished the mitogenic effects of MK on
171  heparinase II requires O-sulfation, whereas heparinase III acts only on the corresponding non-sulfat
172  lost upon digestion of tissue sections with heparinase III and chondroitinase ABC.
173                                              Heparinase III and human heparanase specifically cleaved
174 fate, because this activity was abolished by heparinase III digestion of the cells.
175 95 and histidine 510, as being essential for heparinase III enzymatic activity.
176                                              Heparinase III is the unique member of the heparinase fa
177 ion of heparin and the hydrolysis of HSPG by heparinase III only partially inhibited hIIA PLA2 bindin
178  Removal of the HSs from the cell surface by heparinase III or by silencing syndecan-3 by siRNA parti
179                       Enzymatic treatment by heparinase III or chondroitinase ABC also releases TIMP-
180 , and pretreatment of endothelial cells with heparinase III or protease reduced dengue infectivity by
181 of heparan sulfate proteoglycans (HSPG) with heparinase III prevented infection and BM binding by the
182           Moreover, treatment of HUVECs with heparinase III to specifically eliminate the FGF-2 hepar
183 fen, and enzymatic removal of HS chains with heparinase III treatment as well as by site-directed mut
184                                 In contrast, heparinase III treatment of control cells, with function
185                                              Heparinase III treatment of the genital tract significan
186           Depletion of cell surface HSPGs by heparinase III treatment or decreased glycosaminoglycan
187 rat uterus by heparin/heparan sulfate and by heparinase III treatment.
188 ith a heparan sulfate antibody revealed that heparinase III treatments removed a substantial fraction
189 A(2S)-GlcNH(3)(+)(6S) disaccharides, whereas heparinase III yielded only the DeltaHexA-GlcNH(3)(+) un
190 lowing results: (1) treatment with bacterial heparinase III, an enzyme that degrades heparan sulfate
191 nsitive to digestion of cell surface HS with heparinase III, and TRSB was sensitive to both heparinas
192  was abolished after treating the cells with heparinase III, but not after chondroitinase treatment.
193 , we show that heparinases I and II, but not heparinase III, cleave the AT-III binding site, leaving
194 ate, pretreatment of conditioned medium with heparinase III, or growth of cells in sodium chlorate, i
195  by heparin and by treatment of HBEC-5i with heparinase III, suggesting that the endothelial receptor
196  cells that had been treated with the enzyme heparinase III, which degrades the glycosaminoglycan sid
197                We have prepared a library of heparinase III-generated HS oligosaccharides fractionate
198 te linkages, whereas the other is presumably heparinase III-like, cleaving at hexosamine-glucuronate
199 idines, we examined the role of histidine in heparinase III.
200  TRSB was sensitive to both heparinase I and heparinase III.
201 ct was lost posttreatment of the tissue with heparinase III.
202 as completely inhibited by pretreatment with heparinase III.
203  and this release was blocked by heparin and heparinase III.
204                               Treatment with heparinase-III and p-nitrophenyl-beta-D-xylopyranoside (
205            Heparinase II is unique among the heparinases in that it has broad substrate requirements
206 ndothelial cells, and binding was blocked by heparinase, indicating that secretoneurin stimulates bin
207            Treatment of cells with exogenous heparinase led to a greater than 4-fold increase in apoE
208 availability of HSPG sites as treatment with heparinase or competitors of glycosaminoglycan chain add
209             Treatment of T-cells with either heparinase or heparitinase abolished nucleosome binding
210 urface GAG chains by treatment of cells with heparinase or heparitinase but not chondroitinase marked
211 ll line was also inhibited by digestion with heparinase or heparitinase but not with chondroitinase A
212 fate GAGs on keratinocytes by treatment with heparinase or heparitinase resulted in an 80-90% reducti
213 dothelial cells with chondroitinase, but not heparinase or heparitinase, diminished endothelial bindi
214 is of cell surface HSPGs with, respectively, heparinase or sodium chlorate abrogated HSC adhesion to
215 L1/L2 virus-like particles, is unaffected by heparinase or trypsin pretreatment of HeLa cells.
216 ited by either prior treatment of cells with heparinases or by HS preparations enriched in 3-OS HS.
217 cosaminoglycans in embryonic stem cells with heparinases or sodium chlorate inhibited differentiation
218 oteoglycans because treatment with chlorate, heparinase, or soluble heparin did not prevent Hep II do
219                        Antifibrinolytics and heparinase partially reverse the abnormal clotting patte
220                      Parasite development in heparinase-pretreated HepG2 cells is inhibited by 65% wh
221 ant NOx production that was not inhibited by heparinase pretreatment, demonstrating that the cells we
222                                              Heparinase-pretreatment of LRP-deficient fibroblasts or
223 d plasma samples, which were pretreated with heparinase prior to analysis, had the lowest baseline HI
224                 Blocking FGF1 receptors with heparinase reduced this effect.
225 teract with a widely expressed, trypsin- and heparinase-resistant cell surface molecule and facilitat
226           Pretreatment of cell cultures with heparinase resulted in reduced bFGF binding to the cells
227                                      Soluble heparinase-sensitive GAGs from Idua(-/-) BM and specific
228 tment of chondrocytes with either heparin or heparinase significantly reduced attachment to type XI c
229 eparin, heparan sulfate, sodium chlorate and heparinase, the low-density lipoprotein (LDL) receptor-r
230 L1 to diminish its intravascular function or heparinase to release CXCL1 from endothelial proteoglyca
231 cetic anhydride-d6 is followed by exhaustive heparinase treatment and disaccharide analysis by hydrop
232 a cellular uptake was blocked by heparin and heparinase treatment but not by LRP1 deficiency.
233  of 125I-bFGF to K562 cells was sensitive to heparinase treatment but not to chondroitinase treatment
234  and nonrheumatoid synovia was determined by heparinase treatment followed by an in situ binding assa
235 on assay demonstrated that entry blockage by heparinase treatment included the membrane fusion step.
236                                              Heparinase treatment of the cells did not abrogate this
237                                        After heparinase treatment, LPL binding to apoB17-DAF cells wa
238 heparan sulfate was depressed by chlorate or heparinase treatment.
239 ased 2-10-fold when the HSPG were removed by heparinase treatment.
240      Furthermore, this effect was blocked by heparinase treatment.
241 were still able to produce abundant NO after heparinase treatment.
242 ce heparin-like glycosaminoglycans using the heparinases, we recently have elaborated a mass spectrom
243                                     Finally, heparinases were used to identify and quantify GlcNH(3)(
244 e with heparin or pretreatment of cells with heparinase, which destroys heparan sulfate.
245 in (LRP), but were almost totally blocked by heparinase, which removes the sulfated glycosaminoglycan
246        Intravenous pretreatment of mice with heparinases, which specifically cleave heparan sulfate m

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top